The latest developments across the GLP-1 landscape, from new drug approvals and clinical research to pricing changes and policy shifts. Stay informed on the updates that affect Ozempic, Wegovy, Mounjaro, and the wider category.
News & Updates
Novo Nordisk launched the Wegovy pill in Germany on September 1, 2026, its first European Union market. This article covers the price, OASIS 4 results, how to take the tablet, where else it is available, and why US patients have had access since early 2026.
The FDA has approved Mounjaro to reduce the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes at high cardiovascular risk. This article explains the SURPASS CVOT results, how Mounjaro compares to other GLP-1 options, and what to ask your doctor.
After the GLP-1 boom, investors are turning to pattern hair loss as the next large consumer drug market. This article covers the leading candidates, why hair loss drugs are unlikely to match GLP-1s, and how patients on semaglutide or tirzepatide can manage the temporary hair shedding some experience.
Most employer health plans still exclude GLP-1 medications for weight loss. Using 2025 KFF survey data, this article explains why employers say no, how the companies that cover these drugs manage costs, and what patients can do when their plan denies coverage.
On Jimmy Kimmel Live! in August 2026, Leslie Mann said her husband, director Judd Apatow, has gained about 15 pounds in four years on the highest dose of Ozempic because he likes to override the fullness it creates. His story is a clear example of how GLP-1 medications work and where their limits are.
On August 28, 2026, the FDA approved Mounjaro (tirzepatide) to lower the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes who are at high cardiovascular risk. The approval rests on SURPASS CVOT, which compared Mounjaro head to head with Trulicity. It does not extend to people with obesity who do not have diabetes.
Jelly Roll went from about 540 pounds to 265 and says a GLP-1 played almost no part. He tried one for two weeks early on, then stopped. His story is a useful reminder that there is more than one path to major weight loss, and that GLP-1 medications are a legitimate one.
China's drug regulator has formally accepted Novo Nordisk's application for oral semaglutide, the pill version of Wegovy. This milestone signals growing global demand for convenient GLP-1 options and could have ripple effects on access and pricing worldwide. Here's what patients need to know.